JP Morgan Chase & Co. reduces its stake in ABIVAX

On April 10, 2026, ABIVAX, listed on Euronext Paris, received a declaration from JP Morgan Chase & Co. The group had crossed below the 5% threshold of voting rights in the company. As of April 7, 2026, JP Morgan indirectly held 3,990,154 ABIVAX shares, representing 5.04% of the share capital and 4.89% of the voting rights.

This change results from an off-market sale and a reduction in shares held by assimilation. In particular, JP Morgan Securities LLC and JP Morgan Securities plc each hold various contracts that have implications for their rights to use ABIVAX shares.

Furthermore, equity swap and capp option contracts held by JP Morgan entities continue to influence their overall position on ABIVAX, with maturities extending until April 2033.